Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
May 04, 2022 08:00 ET
|
Applied Genetic Technologies Corporation
– Data reconfirm previously highlighted safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) – GAINESVILLE, Fla., and CAMBRIDGE, Mass., May ...
AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy
May 02, 2022 16:33 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the...
AGTC to Present at Cell & Gene Meeting on the Mediterranean
April 14, 2022 08:00 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
April 04, 2022 16:45 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the...
AGTC Announces Pricing of Public Offering of Common Stock
March 22, 2022 08:45 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development...
AGTC Announces Proposed Public Offering of Common Stock
March 21, 2022 16:01 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development...
AGTC to Participate in Upcoming Investor Conferences
March 08, 2022 16:05 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021
February 14, 2022 07:00 ET
|
Applied Genetic Technologies Corporation
-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass.,...
AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia
February 08, 2022 07:00 ET
|
Applied Genetic Technologies Corporation
AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patientsAt the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and...
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
February 07, 2022 08:00 ET
|
Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development...